

7. **Meye A, Bilkenroth U, Schmidt U, et al.** Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol. *Int J Oncol* 2002; 21: 521–530.
8. **Bluemke K, Bilkenroth U, Meye A, et al.** Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis. *Cancer Epidemiol Biomarkers Prev*. 2009; 18: 2190–2194.
9. **Shimazui T, Yoshikawa K, Uemura H, et al.** Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma. *Int J Oncol* 2003; 23: 1049–1054.
10. **Li G, Passebosc-Faure K, GentilPerret A, et al.** Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells. *Anticancer Res*. 2005; 25: 377–381.
11. **Buchner A, Riesenberger R, Kotter I, et al.** Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma. *Cancer* 2006; 106: 1514–1520.
12. **Basso U, Facchinetti A, Rossi E, et al.** Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma. *J Clin Oncol*. 2017; 35: 4568–4568.
13. **Krebs MG, Metcalf RL, Carter L, et al.** Molecular analysis of circulating tumour cells-biology and biomarkers. *Nat Rev Clin Oncol*. 2014; 11: 129–144.
14. **Palumbo JS, Talmage KE, Massari JV, et al.** Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. *Blood* 2005; 105: 178–185.
15. **Zhang D, Zhao L, Zhou P, et al.** Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy. *Cancer Cell Int*. 2017; 17: 6.
16. **Hou JM, Krebs MG, Lancashire L, et al.** Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. *J Clin Oncol*. 2012; 30: 525–532.
17. **Nagaya N, Kanayama M, Nagata M, Horie S.** The Surge in the Number of Circulating Tumor Cells Following Treatment with Sunitinib for Metastatic Renal Cell Carcinoma. *Intern Med*. 2018; 57(18): 2695–2700.

Do České urologie č. 3 / 2020 připravujeme

- Urologická léčba roztroušené sklerózy
- Léčba následků dlouhodobě navlečeného perlátoru na kořen penisu
- Prevence recidivujících cystitid pomocí roztoku hyaluronátu sodného
- Segmentální infarkt varlete: orchiektomie vs. sledování
- Parciální amputace penisu jako léčba verukózního karcinomu